Overcoming Barriers in Diabetes Management with Individualized Treatment Strategies

Nashville, TN US
May 14, 2015

Thursday, May 14, 2015 | 5:15 – 7:30 AM CST
Omni Nashville Hotel, Legends Ballroom EFG

This course is a live CME-accredited ancillary symposium presented at AACE 2015, the American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress, held in Nashville, Tennessee, May 13–18, 2015.

This activity is supported by an educational grant from sanofi-aventis U.S. Inc. 

SYMPOSIUM AGENDA

Welcome and Introduction
Program Director: Etie Moghissi, MD, FACP, FACE – UCLA David School of Medicine

Early Initiation of Insulin Therapy + Back to Basals: Optimizing Basal Insulin Therapy
Zachary Bloomgarden, MD, MACE – Mount Sinai School of Medicine

Management of the Severely Insulin Resistant Patient
Lisa R. Tannock, MD – University of Kentucky

Meeting Targets with New and Emerging Therapies
Lawrence Blonde, MD, FACP, FACE – Ochsner Diabetes Center

Roundtable Discussion

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Summarize current clinical findings on the benefits of early insulin initiation on long-term patient outcomes
  • Select the most appropriate basal insulin taking into consideration the various pharmacokinetics of new and emerging formulations
  • Discuss strategies to overcome barriers in initiating insulin and optimizing basal insulin therapy
  • Devise therapeutic strategies for insulin resistant patients taking into consideration new and emerging formulations of concentrated insulins
  • Discuss the benefits and limitations of emerging therapies

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Course opens: 
05/14/2015
Course expires: 
05/14/2016
Event starts: 
05/14/2015 - 5:15am
Event ends: 
05/14/2015 - 7:30am
Rating: 
0
Omni Nashville Hotel
205 5th Avenue
Legends Ballroom EFG
Nashville, TN 37203
United States

Etie Moghissi, MD, FACP, FACE – Program Director
Associate Clinical Professor of Medicine
UCLA David Geffen School of Medicine
Consultant in Diabetes, Endocrinology and Metabolism
Marina del Rey California
Los Angeles, California

Zachary T. Bloomgarden, MD, MACE
Editor, the Journal of Diabetes
Clinical Professor of Medicine
Mount Sinai School of Medicine
New York, New York

Lisa R. Tannock, MD
Chief, Division of Endocrinology and Molecular Medicine
Associate Chair of Medicine for Administration
University of Kentucky
Lexington, Kentucky

Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana

DISCLOSURE POLICY

It is the policy of AACE to ensure balance, independence, objectivity and scientific rigor in all of its CME activities.  Presentation content may include discussion of an unlabeled or an investigational use of a product.  AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature. 

Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest.  AACE requires speakers, faculty, CME Committee and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.  All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation and educational materials used as basis for content, and appropriateness of patient care recommendations. 

The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments.  Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence. 

AACE has reviewed all disclosures and resolved or managed all identified conflicts of interest for this educational activity, as applicable.

Dr. Etie Moghissi reports that she has received consultant fees from AstraZeneca, speaker fees from Boehringer Ingelheim GmbH, Janssen Global Services LLC, and Takeda Pharmaceutical Company Limited, and consultant/speaker fees from Novo Nordisk A/S and Merck & Co. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Moghissi has an identified conflict of interest and it has been resolved accordingly. She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Zachary Bloomgarden reports that he has received speaker honoraria from Merck & Co. and Santarus Inc.; speaker/consultant honoraria from Johnson & Johnson Services, Inc. and Novo Nordisk A/S; consultant honoraria from Amgen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb/AstraZeneca; stockholder earnings from Abbott, Covidien, Hospira, Pfizer Inc., F. Hoffman La-Roche Ltd, St. Jude Medical, Inc., and Zoetis; and consultant/stockholder earnings from Novartis AG. He also reports that his presentation will include investigational or unlabeled uses of new insulin preparations for the treatment of diabetes. Dr. Bloomgarden has an identified conflict of interest and it has been resolved accordingly. He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Lisa Tannock reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tannock has no identified conflicts of interest.

Dr. Lawrence Blonde reports that he has received research grant support to his institution for his role as Investigator from Eli Lilly and Company, Novo Nordisk, and sanofi, speaker/consultant honoraria from AstraZeneca, Janssen Pharmaceuticals, Inc.,  Merck & Co., Novo Nordisk, and Sanofi, consultant honoraria from GlaxoSmithKline, Intarcia Therapeutics, Inc., and Quest Diagnostics. He also reports that his presentation will include discussion of investigational or unlabeled use(s) of therapies for treatment of diabetes. Dr. Blonde has an identified conflict of interest and it has been resolved accordingly. He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

American Association of Clinical Endocrinologists and Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

Accreditation Period

Course opens: 
05/14/2015
Course expires: 
05/14/2016